Prof. Toh Han Chong
Organization: National Cancer Centre Singapore
Project Name: ASCOLT STUDY (phase III): Aspirin as an Adjuvant Therapy for Colorectal Cancer
Funding Year: 2016
Project period: 5 years
ASCOLT STUDY (phase III): Aspirin as an Adjuvant Therapy for Colorectal Cancer
This phase III trial will assess the effectiveness of daily aspirin against placebo control in stage 2 and 3 patients. This is an international collaboration led by researchers in Singapore, UK, and Australia, and involves 50 sites in 11 countries across Asia.
The ASCOLT study is a clinical trial that is being undertaken to investigate if aspirin can the recurrence of colorectal cancer after surgery and chemotherapy. The trial is a large international phase 3 study involving more than 60 hospitals in more than 12 countries and has recruited more than 1500 patients to date. In the past decade, there have been numerous trials exploring the use of new chemotherapy agents and biological agents in the prevention of colorectal cancer recurrence. These trials have failed to show benefit. Aspirin is now considered an important prospect and together with the AddAspirin study, the attention of the scientific community is on ASCOLT - to deliver important information on the utility of aspirin in this setting. Numerous observational studies have demonstrated the benefit of aspirin in early stage resected colorectal cancer. A positive finding in ASCOLT will change the practice of colorectal cancer and save many lives globally. Because aspirin is cheap and costs a penny, the repurposing of aspirin as a cancer treatment drug will open a large avenue for its use in colorectal cancer and potentially other cancers.